Triple vs. Dual Antiplatelet Therapy in Patients With Acute Myocardial Infarction and Renal Dysfunction - Results From the Korea Acute Myocardial Infarction Registry -

Circulation Journal

Volumn 76, Issue 10, 2012, Pages 2405-2411

  Choi, Young Hwan ^a   Suh, Sang Heon ^a   Choi, Joon Seok ^a   Kim, Chang Seong ^a   Sim, Doo Sun ^a,b   Bae, Eun Hui ^a   Lim, Sang Yup ^c   Ma, Seong Kwon ^a   Jeong, Myung Ho ^a,b   Kim, Soo Wan ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Acute myocardial infarction; Cilostazol; Glomerular filtration rate; Major adverse cardiac event; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CILOSTAZOL; CREATININE; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ASPIRIN; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; SURVIVAL RATE; TETRAZOLES; TICLOPIDINE;

EID: 84867893578     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0236     Document Type: Article

References (30)

1. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966-2972.
2. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94: 300-305.
3. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119.
4. Mishkel GJ, Varghese JJ, Moore AL, Aguirre F, Markwell SJ, Shelton M. Short and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol 2007; 19: 331-337.
5. Ota T, Umeda H, Yokota S, Miyata S, Takamura A, Sugino S, et al. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J 2009; 158: 92-98.
6. Bae EH, Lim SY, Choi YH, Suh SH, Cho KH, Choi JS, et al; Korea Acute Myocardial Infarction Registry investigators. Drug-eluting vs. bare-metal stents for treatment of acute myocardial infarction with renal insufficiency. Circ J 2011; 75: 2798-2804.
7. Park KW, Hwang SJ, Kwon DA, Oh BH, Park YB, Chae IH, et al; Korea Stent Thrombosis Investigators. Characteristics and predictors of drug-eluting stent thrombosis: Results from the multicenter 'Korea Stent Thrombosis (KoST)' registry. Circ J 2011; 75: 1626-1632.
8. Soslau G, Brodsky I, Putatunda B. Selective reduction of serotonin storage and ATP release in chronic renal failure patients' platelets. Am J Hematol 1990; 35: 171-178.
9. Malyszko J, Malyszko JS, Pawlak D. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 1996; 83: 351-361.
10. Mezzano D, Tagle R, Panes O. Hemostatic disorder of uremia: The platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-321.
11. Mezzano D, Tagle R, Pais E. Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure. Thromb Res 1997; 88: 465-472.
12. Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6: 3-11.
13. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-1275.
14. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
15. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and-LONG Trials). Am J Cardiol 2010; 105: 168-173.
16. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011; 162: 548-554.
17. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
18. Wartak SA, Lotfi A, Rothberg M. Ticagrelor versus clopidogrel in acute coronary syndromes. N Engl J Med 2009; 361: 2386-2387.
19. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.
20. Park SH, Kim W, Park CS. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295.
21. Cuisset T, Frere C, Moro PJ, Quilici J, Pons C, Gaborit B, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome. Thromb Res 2010; 126: e400-e402.
22. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100: 21-26.
23. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
24. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drugeluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: The DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181-1187.
25. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomized trials. Eurointervention 2009; 5: 384-393.
26. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
27. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
28. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCELAMI) study. Circ Cardiovasc Interv 2010; 3: 17-26.
29. Woo JS, Kim W, Lee SR, Jung KH, Kim WS, Lew JH, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 2011; 162: 1018-1025.
30. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of CILostazol- based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.